JO3658B1 - بروتينات اندماج - Google Patents

بروتينات اندماج

Info

Publication number
JO3658B1
JO3658B1 JOP/2016/0076A JOP20160076A JO3658B1 JO 3658 B1 JO3658 B1 JO 3658B1 JO P20160076 A JOP20160076 A JO P20160076A JO 3658 B1 JO3658 B1 JO 3658B1
Authority
JO
Jordan
Prior art keywords
span
fusion proteins
dir
ltr
present
Prior art date
Application number
JOP/2016/0076A
Other languages
English (en)
Inventor
Bruce Baldwin David
Duane Dickinson Craig
Alan Lazar Gregory
Wesley Day Johnathan
Ihor Korytko Andrew
Michael Beals John
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55953435&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3658(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3658B1 publication Critical patent/JO3658B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

يتعلق الاختراع الحالي ببروتينات اندماج تشتمل على مساعد مستقبل إنسولين مدمج مع منطقة<span dir="LTR">Fc </span> <span dir="LTR">IgG</span> بشرية من خلال استخدام رابط ببتيد، واستخدام بروتينات الاندماج المذكورة في معالجة مرض السكري. يكون لبروتينات الاندماج للاختراع الحالي خاصية ممتدة المفعول وتكون نافعة في توفير تحكم في مستوى الجلوكوز القاعدة لفترة زمنية ممتدة<span dir="LTR">.</span>
JOP/2016/0076A 2015-05-07 2016-04-21 بروتينات اندماج JO3658B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562158079P 2015-05-07 2015-05-07

Publications (1)

Publication Number Publication Date
JO3658B1 true JO3658B1 (ar) 2020-08-27

Family

ID=55953435

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2016/0076A JO3658B1 (ar) 2015-05-07 2016-04-21 بروتينات اندماج

Country Status (40)

Country Link
US (5) US9855318B2 (ar)
EP (1) EP3292141B1 (ar)
JP (1) JP6591562B2 (ar)
KR (1) KR102059736B1 (ar)
CN (1) CN107531806B (ar)
AR (1) AR105616A1 (ar)
AU (1) AU2016257659B2 (ar)
CA (1) CA2981102A1 (ar)
CL (1) CL2017002761A1 (ar)
CO (1) CO2017011301A2 (ar)
CR (1) CR20170469A (ar)
CY (1) CY1122929T1 (ar)
DK (1) DK3292141T3 (ar)
DO (1) DOP2017000258A (ar)
EA (1) EA039770B1 (ar)
EC (1) ECSP17073650A (ar)
ES (1) ES2799099T3 (ar)
HR (1) HRP20200503T1 (ar)
IL (1) IL254965B (ar)
JO (1) JO3658B1 (ar)
LT (1) LT3292141T (ar)
MA (1) MA42037B1 (ar)
MD (1) MD3292141T2 (ar)
ME (1) ME03709B (ar)
MX (1) MX388594B (ar)
MY (1) MY183025A (ar)
NZ (1) NZ736470A (ar)
PE (1) PE20180507A1 (ar)
PH (1) PH12017502025A1 (ar)
PL (1) PL3292141T3 (ar)
PT (1) PT3292141T (ar)
RS (1) RS60044B1 (ar)
SG (1) SG11201708194WA (ar)
SI (1) SI3292141T1 (ar)
SV (1) SV2017005548A (ar)
TN (1) TN2018000059A1 (ar)
TW (1) TWI656132B (ar)
UA (1) UA122146C2 (ar)
WO (1) WO2016178905A1 (ar)
ZA (1) ZA201706334B (ar)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107743494B (zh) 2015-06-02 2022-04-29 诺和诺德股份有限公司 具有极性重组延伸体的胰岛素
EP3355931B1 (en) 2015-10-01 2024-06-26 Novo Nordisk A/S Protein conjugates
SG11201811527VA (en) 2016-07-27 2019-01-30 Hewlett Packard Development Co Lp Horizontal interface for fluid supply cartridge having digital fluid level sensor
WO2018107117A1 (en) 2016-12-09 2018-06-14 Akston Biosciences Corporation Insulin-fc fusions and methods of use
TR201703622A1 (tr) * 2017-03-09 2018-09-21 Univ Yeditepe Obezi̇te tedavi̇si̇ i̇çi̇n bi̇r ürün
MA49339A (fr) * 2017-04-05 2020-02-12 Novo Nordisk As Conjugués insuline-fc à extension oligomère
LT3743088T (lt) 2018-01-26 2022-12-27 F. Hoffmann-La Roche Ag Il-22 fc kompozicijos ir jų naudojimo būdai
EP3810640A1 (en) 2018-06-25 2021-04-28 University of Washington De novo design of potent and selective interleukin mimetics
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
CN113038964B (zh) * 2018-06-29 2025-05-27 德克拉有限公司 超长效胰岛素-fc融合蛋白及使用方法
JP2022502467A (ja) 2018-10-10 2022-01-11 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−ｆｃコンジュゲートおよびそれらの医学的使用
JP2022511390A (ja) 2018-11-20 2022-01-31 ユニバーシティ オブ ワシントン 分割インターロイキン模倣体およびその使用
CN113613629A (zh) * 2019-03-15 2021-11-05 伊莱利利公司 防腐的制剂
WO2021011827A1 (en) * 2019-07-16 2021-01-21 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
TW202434620A (zh) 2019-07-31 2024-09-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
HUE064376T2 (hu) * 2019-12-19 2024-03-28 Akston Biosciences Corp Ultra-hosszú hatású inzulin-FC fúziós fehérjék és felhasználási eljárások
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US20230340071A1 (en) 2020-03-16 2023-10-26 Neoleukin Therapeutics, Inc. Interleukin-2 Receptor Beta (IL-2RB) Binding Polypeptides
JP2023521706A (ja) 2020-04-07 2023-05-25 ネオロイキン セラピューティクス， インコーポレイテッド アンギオテンシン変換酵素２（ａｃｅ２）のデノボタンパク質デコイ
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
KR102898622B1 (ko) 2020-04-10 2025-12-12 악스톤 바이오사이언시스 코퍼레이션 Covid-19 융합 단백질에 대한 항원 특이적 면역요법 및 사용 방법
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
EP4230216A4 (en) * 2020-07-24 2025-02-19 Jiangsu Gensciences Inc. Insulin-fc fusion protein and application thereof
KR20230098335A (ko) * 2020-11-06 2023-07-03 암젠 인크 클리핑 비율이 감소된 항원 결합 도메인
WO2022132709A1 (en) * 2020-12-14 2022-06-23 Eli Lilly And Company Methods of treating diabetes
WO2023004406A2 (en) 2021-07-23 2023-01-26 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer
WO2023044318A2 (en) 2021-09-15 2023-03-23 Neoleukin Therapeutics, Inc. Interleukin-2 receptor βeta (il-2rβ) binding polypeptides
AR127619A1 (es) 2021-11-15 2024-02-14 Lilly Co Eli FORMULACIONES CONSERVADAS DE FUSIONES DE INSULINA-Fc
TW202342552A (zh) * 2022-03-16 2023-11-01 大陸商北京拓界生物醫藥科技有限公司 人胰島素類似物、其融合蛋白及醫藥用途
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs
JP2025522529A (ja) 2022-06-23 2025-07-15 サノフイ 一本鎖インスリン及びそのＦｃ結合体
WO2024137820A1 (en) * 2022-12-20 2024-06-27 The Board Of Trustees Of The Leland Stanford Junior University Insulin receptor antagonist
CN115894720B (zh) * 2023-01-16 2024-07-09 中国科学院上海药物研究所 一种长效胰岛素-Fc融合蛋白
AU2024265269A1 (en) 2023-05-03 2025-11-06 Eli Lilly And Company Methods and systems for managing diabetes
CN121794759A (zh) 2023-09-11 2026-04-03 伊莱利利公司 用于管理糖尿病的方法和系统
CN121752601A (zh) * 2023-09-20 2026-03-27 上海迈晋生物医药科技有限公司 一种人胰岛素类似物融合蛋白的药物组合物及其医药用途
WO2025080923A1 (en) 2023-10-13 2025-04-17 Eli Lilly And Company Insulin-fc fusion proteins
EP4669757A1 (en) 2024-03-21 2025-12-31 Akston Biosciences Corporation PD-L1 ANALOGUE FUSION PROTEINS FOR ANTIGEN-SPECIFIC IMMUNOTHERAPY AND METHODS OF USE

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
NZ250844A (en) 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
AU5724996A (en) 1995-05-05 1996-11-21 Eli Lilly And Company Single chain insulin with high bioactivity
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
CA2369839A1 (en) 1999-06-25 2001-01-04 Minimed, Inc. Compositions of insulin and insulin-related peptide for treating diabetes
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
ES2311560T3 (es) 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
CZ2004710A3 (cs) 2001-12-20 2005-02-16 Eli Lilly And Company Inzulínová sloučenina s protrahovaným účinkem
JP4629047B2 (ja) 2003-06-12 2011-02-09 イーライ リリー アンド カンパニー Ｇｌｐ−１アナログ複合タンパク質
EP1668419B1 (en) 2003-10-02 2010-07-28 Carl Zeiss SMT AG Projection objective for semiconductor lithography
JP5697831B2 (ja) 2003-12-03 2015-04-08 ノヴォ ノルディスク アー／エス 単鎖インシュリン
JP2008533100A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｐｅｇ化された単鎖インスリン
EP1991575A1 (en) 2006-02-21 2008-11-19 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
JP2009530243A (ja) 2006-03-13 2009-08-27 ノボ・ノルデイスク・エー／エス アシル化単鎖インスリン
US20090069215A1 (en) 2006-03-13 2009-03-12 Novo Nordisk A/S Acylated Single Chain Insulin
HUE029512T2 (en) 2006-09-22 2017-03-28 Novo Nordisk As Protease Resistant Insulin Analogs
WO2008043033A2 (en) 2006-10-04 2008-04-10 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
WO2008049711A1 (en) 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
KR100897938B1 (ko) * 2007-05-30 2009-05-18 주식회사 제넥신 면역글로불린 융합 단백질
HRP20110242T1 (hr) 2007-07-10 2011-05-31 Eli Lilly And Company Formulacija s fuzijskim proteinom glp-1-fc
JP5762001B2 (ja) 2008-03-14 2015-08-12 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化インスリンアナログ
WO2009115469A1 (en) * 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
WO2009132129A2 (en) 2008-04-22 2009-10-29 Case Western Reserve University Isoform-specific insulin analogues
GB0812019D0 (en) 2008-07-02 2008-08-06 Asterion Ltd Insulin
TWI388570B (zh) 2008-07-23 2013-03-11 韓美科學有限公司 包含具有三個官能端的非肽醯聚合物的多肽複合物
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101324828B1 (ko) * 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
EP2582719B1 (en) 2010-06-16 2016-08-10 Indiana University Research and Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
DK2672986T3 (da) 2011-02-09 2020-06-08 Glaxosmithkline Llc Frysetørrede formuleringer
CN102718870B (zh) * 2011-05-24 2014-04-30 马鞍山中美德康生物科技有限公司 一种胰岛素生物增敏剂及其应用
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
CN102516393B (zh) * 2011-11-30 2017-03-15 北京康明百奥新药研发有限公司 胰岛素模拟肽融合蛋白和突变体及其应用
CN103509118B (zh) * 2012-06-15 2016-03-23 郭怀祖 胰岛素-Fc融合蛋白
EP2869830B1 (en) 2012-07-09 2016-10-12 Novo Nordisk A/S Novel use of insulin derivatives
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
CN108383902A (zh) 2012-09-26 2018-08-10 印第安纳大学研究及科技有限公司 胰岛素类似物二聚体
JP6584953B2 (ja) 2012-11-05 2019-10-02 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 長時間作用型単鎖インスリン類似体
AR094904A1 (es) 2013-02-26 2015-09-09 Hanmi Pharm Ind Co Ltd Análogos de insulina y su uso
WO2014152955A1 (en) * 2013-03-14 2014-09-25 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
AU2014333979B2 (en) 2013-10-07 2018-02-15 Novo Nordisk A/S Novel derivative of an insulin analogue
AU2015206890B2 (en) 2014-01-20 2019-05-23 Hanmi Pharm. Co., Ltd. Long-acting insulin and use thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
KR20160001391A (ko) 2014-06-27 2016-01-06 한미약품 주식회사 신규한 지속형 인슐린 아날로그 결합체 및 이의 용도
KR20160007295A (ko) 2014-07-11 2016-01-20 한미약품 주식회사 인슐린 아날로그
CA2961037A1 (en) 2014-10-06 2016-04-14 Case Western Reserve University Biphasic single-chain insulin analogues
PH12017500935A1 (en) 2014-11-21 2017-11-27 Merck Sharp & Dohme Insulin receptor partial agonists
JP2018508504A (ja) 2015-02-17 2018-03-29 ハンミ ファーマシューティカル カンパニー リミテッド 持続型インスリンまたはインスリンアナログ結合体
CN110134210A (zh) 2019-04-16 2019-08-16 深圳市国鑫恒宇科技有限公司 一种服务器一体机的温度控制方法、系统、装置及存储介质

Also Published As

Publication number Publication date
LT3292141T (lt) 2020-03-25
DOP2017000258A (es) 2017-12-31
CR20170469A (es) 2017-11-14
US11253574B2 (en) 2022-02-22
CY1122929T1 (el) 2021-10-29
MY183025A (en) 2021-02-07
CN107531806A (zh) 2018-01-02
JP2018515088A (ja) 2018-06-14
SI3292141T1 (sl) 2020-04-30
HRP20200503T1 (hr) 2020-06-26
PE20180507A1 (es) 2018-03-09
CN107531806B (zh) 2022-06-07
ES2799099T3 (es) 2020-12-14
NZ736470A (en) 2019-04-26
US20200390865A1 (en) 2020-12-17
BR112017020502A2 (pt) 2018-07-03
CA2981102A1 (en) 2016-11-10
AR105616A1 (es) 2017-10-25
US20220211818A1 (en) 2022-07-07
TWI656132B (zh) 2019-04-11
US9855318B2 (en) 2018-01-02
EP3292141A1 (en) 2018-03-14
US20250032588A1 (en) 2025-01-30
RS60044B1 (sr) 2020-04-30
DK3292141T3 (da) 2020-04-20
JP6591562B2 (ja) 2019-10-16
MA42037B1 (fr) 2020-03-31
IL254965B (en) 2021-03-25
ECSP17073650A (es) 2018-02-28
TN2018000059A1 (en) 2019-07-08
US20160324932A1 (en) 2016-11-10
EA201792199A1 (ru) 2018-03-30
ZA201706334B (en) 2020-01-29
MX2017014284A (es) 2018-03-23
IL254965A0 (en) 2017-12-31
KR102059736B1 (ko) 2019-12-26
CO2017011301A2 (es) 2018-03-20
CL2017002761A1 (es) 2018-05-18
WO2016178905A1 (en) 2016-11-10
US10709766B2 (en) 2020-07-14
US12059452B2 (en) 2024-08-13
PL3292141T3 (pl) 2020-06-29
EA039770B1 (ru) 2022-03-11
SV2017005548A (es) 2018-04-24
PH12017502025B1 (en) 2018-04-02
ME03709B (me) 2021-01-20
PT3292141T (pt) 2020-04-22
AU2016257659A1 (en) 2017-10-12
UA122146C2 (uk) 2020-09-25
HK1244019A1 (en) 2018-07-27
TW201712029A (zh) 2017-04-01
US20180177851A1 (en) 2018-06-28
MD3292141T2 (ro) 2020-07-31
PH12017502025A1 (en) 2018-04-02
AU2016257659B2 (en) 2018-08-09
SG11201708194WA (en) 2017-11-29
EP3292141B1 (en) 2020-02-12
MX388594B (es) 2025-03-20
KR20170134614A (ko) 2017-12-06

Similar Documents

Publication Publication Date Title
CY1122929T1 (el) Πρωτεϊνες συγχωνευσης
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
EP3733716A4 (en) DIMERAL FUSION PROTEIN USING ANTIBODY FC REGION AS A SKELETON AND ASSOCIATED USE
GEAP202114720A (en) Constructs having a sirp-alpha domain or variant thereof
MX2019013023A (es) Proteina de fusion con receptor tgf-?, y uso farmaceutico de la misma.
MX360295B (es) Proteinas de fusion del ligando de ox40 (ox40l) y sus usos.
TW201613958A (en) MIC-1 fusion proteins and uses thereof
GB2564823A8 (en) Compositions and methods for T-cell receptors reprogramming using fusion proteins
BR112017006178A2 (pt) região fc, anticorpos, formulação farmacêutica e usos dos anticorpos
JOP20190097A1 (ar) الجلوبولينات المناعية واستخداماتها
MX2018001787A (es) Proteinas de fusion del ligando de la proteina relacionada con el receptor de factor de necrosis tumoral inducido por glucorticoides (gitrl) y usos de las mismas.
MX2021000083A (es) Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes.
BR112016020377A2 (pt) proteínas fc multiméricas
BR112016023948A2 (pt) proteínas fc multiméricas
UY36021A (es) Proteìnas fc multimèricas
PE20170142A1 (es) Proteina de fusion que inhibe angiogenesis o crecimiento y uso de la misma
CY1124727T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
BR112017028331A2 (pt) proteínas de fusão que se ligam a receptores fc humanos
PH12020500054A1 (en) Novel therapeutic enzyme fusion protein and use thereof
PL3257524T3 (pl) Stabilny preparat farmaceutyczny w postaci roztworu białka fuzyjnego przeciwciała przeciwko glp-1r
EP3808847A4 (en) Apj antibody, fusion protein thereof with elabela, and pharmaceutical compositions and use thereof
EA201991022A1 (ru) Иммуноглобулины и их применение
CY1124859T1 (el) Ομοδιμερικο πεπτιδιο για τη θεραπεια του διαβητη και σχετικων νοσων
EA202090582A3 (ru) Полипептиды il-22, химерные белки il-22 fc и их применение